Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of IKT-001 in Pulmonary Arterial Hypertension
NCT07632898Phase 3Not yet recruiting
- Sponsor
- Inhibikase Therapeutics, Inc.
- Start
- Oct 2026
- Primary completion
- Jun 2030
01
Overview
A Phase 3 trial of IKT-001 in pulmonary arterial hypertension (PAH), sponsored by Inhibikase Therapeutics, Inc.. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
IKT-001
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07632898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07632898.